Tourette syndrome (TS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Tourette syndrome (TS)

Tourette syndrome (TS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

According to Thelansis it is estimated that 200,000 Americans have the most severe form of Tourette syndrome (TS), and as many as one in 100 exhibit milder and less complex symptoms such as chronic motor or vocal tics.

Competitive landscape of Tourette syndrome (TS) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Tourette syndrome (TS) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Tourette syndrome (TS) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Tourette syndrome (TS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company               Stage

1        TEV50717        Teva        Phase III

2        ecopipam        Emalex Biosciences        Phase III

3        dronabinol + palmitoylethanolamide        Therapix Biosciences        Phase II

4        ABX1431        Lundbeck        Phase II

5        CPP-115        Catalyst Pharmaceuticals        Phase II

6        MT 5199        Mitsubishi Tanabe Pharma        Phase II

7        ADS5102        Adamas Pharmaceuticals        Preclinical

8        Amfetamine prodrug        KemPharm        Preclinical

9        Bevantolol        Nippon Chemiphar        Preclinical

10      GABAA modulating steroid antagonists        Asarina Pharma        Preclinical

11      Sepranolone        Asarina Pharma        Preclinical